Literature DB >> 8074917

Acute myeloid leukaemia in patients with trisomy 21 (Down syndrome) treated by bone marrow transplantation.

A Goleta-Dy1, L Dalla Pozza, P J Shaw, M M Stevens.   

Abstract

Patients with trisomy 21 have an increased incidence of haematological disorders, including neonatal 'leukaemoid reaction' (transient myeloproliferative disorder [TMD]), and acute leukaemias. In the past it has been felt that patients with trisomy 21 and acute leukaemia do not tolerate, and hence may not warrant, therapy as intensive as those without the syndrome. The present authors' experience and the current literature do not support this view. Two cases are reported of acute myeloid leukaemia in children with trisomy 21, successfully treated with intensive chemotherapy and bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074917     DOI: 10.1111/j.1440-1754.1994.tb00634.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  2 in total

1.  Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Authors:  Johann K Hitzler; Wensheng He; John Doyle; Mitchell Cairo; Bruce M Camitta; Ka Wah Chan; Miguel A Diaz Perez; Christopher Fraser; Thomas G Gross; John T Horan; Alana A Kennedy-Nasser; Carrie Kitko; Joanne Kurtzberg; Leslie Lehmann; Tracey O'Brien; Michael A Pulsipher; Franklin O Smith; Mei-Jie Zhang; Mary Eapen; Paul A Carpenter
Journal:  Pediatr Blood Cancer       Date:  2014-01-04       Impact factor: 3.167

2.  Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.

Authors:  Johann K Hitzler; Wensheng He; John Doyle; Mitchell Cairo; Bruce M Camitta; Ka Wah Chan; Miguel A Diaz Perez; Christopher Fraser; Thomas G Gross; John T Horan; Alana A Kennedy-Nasser; Carrie Kitko; Joanne Kurtzberg; Leslie Lehmann; Tracey O'Brien; Michael A Pulsipher; Franklin O Smith; Mei-Jie Zhang; Mary Eapen; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-01       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.